| abstract |
New compounds derived from benzimidazole, according to Formula lb, that decrease MYC protein (c-MYC) in cells and / or inhibit histone acetyltransferase p300 / CBP and may be useful in the treatment of cardiac hypertrophy, diabetes, obesity and disease of non-alcoholic fatty liver, HIV, polycystic kidney disease, inflammatory diseases, ankylosing spondylitis, psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, multiple sclerosis, cancer and precancerous syndromes, and diseases associated with Myc deregulation or inhibition of histone acetyltransferase p300 / CBP. |